35 results about "Tumor burden" patented technology

The invention relates to a recombinant complement protein and application thereof in preparation of anti-leukemia drugs, and belongs to the technical field of biological medicines. The invention discloses a method for treating acute leukemia by single drug, namely injecting recombinant C1QBP protein, which has a remarkable effect on treating acute leukemia, can be used for remarkably inhibiting proliferation of leukemia cells in marrow, spleen and peripheral blood of a hematopoietic system and also inhibiting infiltration of the leukemia cells in extramedullary organs (skin and the like), so that the whole-body tumor load is reduced, and the curative effect of treating acute leukemia is improved. The lifetime of leukemia mice is obviously prolonged. The recombinant C1QBP protein is combined with a clinical first-line chemotherapy regimen for use, has a synergistic effect, has a stronger effect of inhibiting leukemia cell proliferation compared with a single chemotherapy drug, can significantly prolong the lifetime of leukemia mice, and plays a role in reducing toxicity and enhancing efficacy. The invention proves that the complement C1Q binding protein has the effect of treating leukemia for the first time, provides a preparation method and a drug combination scheme, and has relatively high clinical transformation prospect and application value.

The invention discloses a therapeutic target CD40 related to multiple myeloma bone diseases and application of a monoclonal antibody of the therapeutic target CD40. On one hand, it is found that formation and osteogenic differentiation of primary cilia of BMSCs can be effectively recovered by adding a CD40 neutralizing antibody into an MM-BMSCs co-culture system; on the other hand, the CD40 neutralizing antibody is found to reduce bone destruction and tumor load in a Vk * MYC myeloma mouse model. CD40 is expected to become a potential target spot for treating multiple myeloma bone diseases and has a very wide application prospect in the field of medical research.

The invention discloses a plant lactobacillus AR195 strain and application thereof in preparation of a medicine for preventing and / or treating lung cancer, and belongs to the technical field of microorganisms. Through verification, the plant lactobacillus AR195 can inhibit the growth of lung cancer cells, also has certain prevention and treatment effects in a lung cancer mouse model, and can reduce the tumor burden of a BALB / c mouse lung cancer model by reducing MMP9 secretion, so that the plant lactobacillus AR195 can be used for preventing and assisting in treating lung cancer. Meanwhile, the accumulation of the AR195 bacteria in the lung can be improved to the maximum extent through atomization administration, and meanwhile, the adverse side effects of the whole body are reduced. A new drug source is provided for treatment of lung cancer, a novel treatment strategy is provided for treatment of lung cancer by probiotics, and treatment of lung cancer and development of a novel treatment method are facilitated. Meanwhile, the application range of the plant lactobacillus AR195 strain is widened, and a novel treatment strategy is provided for a potential mechanism of treating lung cancer by probiotics.

This invention relates to the field of leukemia research, specifically disclosing an animal model of CAR-T therapy for leukemia complicated by cytokine release syndrome (CRS), its preparation method, and its application. The method for preparing the animal model of CAR-T therapy for leukemia complicated by CRS includes: obtaining CD19 CAR-T cells: peripheral blood mononuclear cell isolation, T cell magnetic bead sorting, T cell activation, lentiviral infection, and CAR-T cell expansion; constructing an animal model of CRS after high- and low-dose CAR-T infusion: implanting Nalm-6 cell line into living animals to induce leukemia tumor burden, obtaining living animals with leukemia tumor burden, and injecting CD19 CAR-T cell line into the living animals with leukemia tumor burden. This invention provides a novel application for the animal model of CAR-T therapy for leukemia complicated by cytokine release syndrome. By using severely combined immunodeficient mice and inoculating them with high- and low-burden tumor cells, and infusing different doses of CAR-T cells, this invention constructs an in vivo model that can simulate clinical CRS, providing research guidance for clinically exploring more effective interventions.

The present disclosure provides methods and systems for screening or detecting colorectal cancer or subsequent colorectal disease progression, which can be applied to cell-free nucleic acids, such as cell-free DNA. The methods can train a machine learning model using detection of methylation signals within single sequencing reads in identified genomic regions as input features, and generate a classifier suitable for stratifying a population of individuals. The methods can include extracting DNA from a cell-free sample obtained from a subject, transforming the DNA for methylation sequencing, generating sequencing reads, and detecting colon proliferative cell disorder related signals in the sequencing information, and training a machine learning model to provide a discriminator capable of distinguishing between groups such as healthy, cancer, etc. in a population of subjects, or distinguishing between disease subtypes or stages. The methods can be used, for example, to predict, prognosticate, and / or monitor response to treatment, tumor burden, recurrence, or progression of colorectal cancer.

The present disclosure provides a probe set for judging the systemic tumor burden of triple-negative breast cancer and application thereof, the probe set provided by the present disclosure can be used for detecting the gene markers of triple-negative breast cancer and for evaluating the systemic tumor burden, and can achieve good coverage and capture of the target region, obtain sufficient read information on the target region, and overcome the spatial and temporal heterogeneity of tumors to a certain extent, while improving the capture efficiency, stabilizing the experimental system, and meeting the requirements of clinical detection.

The invention provides an antisense oligonucleotide (ASO), the antisense oligonucleotide is complementary with a CREPT gene sequence, the expression of CREPT can be effectively inhibited, and the antisense oligonucleotide is selected from antisense oligonucleotides with any one nucleotide sequence as shown in SEQ ID No.1-3. The antisense oligonucleotide (ASO) can efficiently and specifically target CREPT, the expression level of CREPT in tumor cells is significantly reduced, the clone formation ability of the tumor cells is further reduced, and the invasion ability of the tumor cells is significantly reduced. The invention further provides an extracellular vesicle and a pharmaceutical composition, and tumor load can be remarkably reduced after the extracellular vesicle is applied to a patient. The antisense oligonucleotide (ASO) of the invention can be used for treating liver cancer.

The presently disclosed subject matter provides cells, compositions, and methods for enhancing immune responses to tumor antigens. These cells comprise a first antigen-recognizing receptor that targets CD70. These cells have improved activity and / or efficiency. The present invention also provides a method for reducing tumor burden in a subject with renal cell carcinoma, pancreatic cancer, or ovarian cancer, comprising administering to the subject an effective amount of cells comprising a TCR-like fusion molecule that targets CD70.

Provided are pharmaceutical compositions for reducing a tumor burden in a subject having a cancer comprising a combination therapy comprising a therapeutically effective dose of a modified CD2 polypeptide derived from human or rat domain one of CD2 polypeptide and a second therapeutic agent comprising an immune checkpoint inhibitor. Also provided are methods of inhibiting or reducing tumor growth and methods of synergistically increasing the activity of an anti-PD-L1 immunotherapeutic in a subject having a cancer comprising administering the pharmaceutical compositions.

Embodiments of the present disclosure pertain to methods of assessing glioma in a subject by (1) receiving a plurality of measured biomarker levels of the subject; and (2) assessing glioma in the subject based on the measured biomarker levels by at least correlating differentially expressed levels of the measured biomarkers to at least one of (a) diagnosis of glioma, (b) progression of glioma, (c) treatment outcome, and / or (d) tumor burden. The methods of the present disclosure also include a step of (3) making a treatment decision based on the assessment. Additional embodiments of the present disclosure pertain to systems for assessing glioma in a subject.

This invention relates to the application of AMPA receptor antagonists in the preparation of drugs for treating peritoneal metastases of gastric cancer, belonging to the field of biomedical technology. This invention discloses the application of GRIA2 as a drug target in the preparation of drugs for the prevention or treatment of peritoneal metastases of gastric cancer. It discloses the use of AMPA receptor antagonists NBQX and / or Selurampanel in the preparation of drugs for the prevention or treatment of peritoneal metastases of gastric cancer. NBQX and Selurampanel can significantly inhibit the migration, invasion, spheroidization ability, and adhesion to mesothelial cells of gastric cancer cells; in vivo experiments have confirmed that AMPA receptor antagonists can significantly reduce tumor burden and the number of metastatic nodules in a mouse model of peritoneal metastases of gastric cancer. Patient-derived organoid xenograft models further demonstrate that AMPA receptor antagonists have significant efficacy against peritoneal metastases of gastric cancer with high GRIA2 expression. This invention provides a new treatment strategy for peritoneal metastases of gastric cancer.

The present disclosure provides materials and methods for assessing and / or treating subjects having prostate cancer. In some embodiments, materials and methods for assessing a subject's tumor burden using a liquid biomarker, tumor-derived extracellular vesicle expressing a surface antigen, are provided. Provided are materials and methods for using the presence or absence of the biomarker to assess whether a subject should be treated with radiotherapy alone, or whether the subject would benefit from systemic therapy, either alone or in combination with radiotherapy.

The invention discloses siRNA (small interfering Ribonucleic Acid) for inhibiting the expression of a CREPT gene. The nucleotide sequence of a positive-sense strand of the siRNA is shown as any one of SEQ ID No. 1 to SEQ ID No. 3. The siRNA can be used for inhibiting CREPT (Cathode Reactive Part of siRNA can inhibit the growth of mouse colon cancer cells and the growth of NIH3T3 fibroblast cells. And the drug can be delivered through the liposome of the delivery system si-CREPT, so that the mouse liver cancer can be treated, and the tumor load of the mouse liver cancer can be remarkably reduced.

The present invention relates to C-X-C motif chemokine ligand 10 (CXCL10) binding proteins and their use in methods of detecting and / or diagnosing a condition in a subject, including determining the level of CXCL10 in a subject. Specific antibodies that bind total CXCL10 (full length, N-terminally truncated and citrullinated) and antibodies that bind active CXCL10 (full length) are used to measure the level of total CXCL10 and active CXCL10 in ovarian cancer patient samples. The calculated ratio between active CXCL10 and total CXCL10 is lower in patients with malignant disease compared to patients with benign tumors or healthy individuals, and this calculated ratio is the basis for methods of diagnosing malignant disease, monitoring tumor burden and disease progression.

The invention relates to application of BAHD1 as a target spot in preparation of leukemia treatment drugs, and belongs to the technical field of biological medicines. In order to solve the ubiquitous problems of high drug resistance and high recurrence of acute leukemia treatment schemes, the invention provides application of BAHD1 as a target spot in preparation of leukemia treatment drugs. The invention proves that BAHD1 is highly expressed in acute leukemia cells and is used as a molecular marker for diagnosis of acute leukemia. The invention proves that the knockout of BAHD1 significantly inhibits proliferation and self-renewal of acute leukemia cells and promotes apoptosis and differentiation of the acute leukemia cells; the proliferation of in-vivo leukemia cells is effectively inhibited, the tumor load and extramedullary infiltration are reduced, and the lifetime is remarkably prolonged. In addition, by knocking out BAHD1, the sensitivity of acute leukemia cells to traditional chemotherapeutic drugs and targeted therapeutic drugs can be remarkably enhanced.

The present disclosure provides technologies for target entity detection. One aspect of the present disclosure provides technologies for detection (e.g., early detection) of a disease, disorder, or condition (e.g., cancer). In another aspect, technologies provided herein are useful for selecting and / or monitoring and / or evaluating efficacy of, a treatment administered to a subject in need thereof, e.g., a subject determined to have or susceptible to cancer. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by measuring tumor burdens and changes in tumor burdens in conjunction with therapeutics.

The present disclosure is directed to methods of treating or ameliorating various conditions by the administration of a BCN057, BCN512 or analogs of these compounds. The compounds can be used to reduce tumor burden in cancers, including pancreatic cancer and gastrointestinal (GI) cancer. The compounds can also be used to protect against chemotherapy induced toxicity to the GI tract. Further, they can be used to treat fibrosis and various inflammatory conditions. Analogs of BCN057 and BCN512 are also described.

The present disclosure in one aspect provides technologies for detection of liver cancer, e.g., early detection of liver cancer. In another aspect, technologies provided herein are useful for selecting and / or monitoring and / or evaluating efficacy of, a treatment administered to a subject determined to have or susceptible to liver cancer. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by measuring tumor burdens and changes in tumor burdens in conjunction with therapeutics. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by identifying biomarkers in subjects' bodily fluid samples (e.g., blood samples) that are associated with therapeutic response.

Methods and uses are disclosed for treating an adrenal tumor in a subject suffering from an adrenal tumor to reduce the size or tumor load of the adrenal tumor, prevent its growth, or slow its growth, or reduce or alter its secretion, or induce its degeneration or apoptosis. The novel methods of treatment include the use or administration of an effective amount of a glucocorticoid receptor modulator (GRM) compound having a heteroaryl-ketone fused aza-naphthane structure to a patient suffering from an adrenal tumor. The adrenal tumor may be a benign adrenal tumor. In some embodiments, GRM may be reracolan, which is ((R)-(1-(4-fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl) sulfonyl)-4, 4a, 5, 6, 7, 8-hexahydro-1H-pyrazolo [3, 4-g] isoquinolin-4a-yl) (4-(trifluoromethyl) pyridin-2-yl) methanone). The GRM may be administered orally. The GRM may be administered with a food. The treatment methods can be used before, during or after an adrenal tumor operation, and can also be used without an operation. The use of these therapeutic methods may not adversely affect normal adrenal gland tissue.

This patent discloses a method for detecting a patient's tumor burden. DNA is extracted from a patient's tumor tissue sample, a predetermined number of biomarker genes are selected to form a biomarker gene cluster ("customized gene cluster"). A DNA sample of circulating free cells in the patient's body fluid is isolated. DNA sequences containing biomarker genes are enriched in the free DNA fragments. The enriched DNA is sequenced. The mutant and normal DNA sequences in the enriched DNA are counted. The patient's tumor burden is then determined. Preferably, mutations in therapeutically relevant genes ("drug-targeted genes") are detected simultaneously with the detection of the customized gene cluster.

The present disclosure in one aspect provides technologies for detection of ovarian cancer, e.g., early detection of ovarian cancer. In another aspect, technologies provided herein are useful for selecting and / or monitoring and / or evaluating efficacy of, a treatment administered to a subject determined to have or susceptible to ovarian cancer. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by measuring tumor burdens and changes in tumor burdens in conjunction with therapeutics. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by identifying biomarkers in female subjects' bodily fluid samples (e.g., blood samples) that are associated with therapeutic response. In some embodiments, technologies provided herein are useful for differentiating a benign adnexal mass from ovarian cancer.

This invention relates to the preparation and application of an oncolytic virus that specifically promotes the rupture of tumor cell plasma membranes. Specifically, this invention utilizes a glioblastoma-specific Nestin enhancer or a tumor cell-specific Survivin promoter to drive the specific expression of the NINJ1 or DTA gene, thereby enhancing the lytic and killing ability of cells. The oncolytic virus G005 expressing NINJ1 exhibits strong killing ability against tumor cells, and the tumor completely disappears in an orthotopic glioma animal model. It can also rapidly restore the weight loss in mice caused by tumor burden, demonstrating that the oncolytic virus G005 has excellent therapeutic effects against GBM.

The presently disclosed subject matter provides cells, compositions, and methods for enhancing immune responses to tumor antigens. These cells comprise a first antigen-recognizing receptor (e.g., a chimeric antigen receptor (CAR)) and a second antigen-recognizing receptor (e.g., a TCR-like fusion molecule). These cells have improved activity and / or efficiency. The presently disclosed subject matter further provides uses of these compositions in reducing tumor burden, treating and / or preventing neoplasms or tumors, preventing and / or treating pathogen infections, preventing and / or treating autoimmune diseases, and / or preventing and / or treating infectious diseases.

The application discloses a probe set for evaluating systemic tumor burden of pancreatic cancer and application thereof, wherein the probe set comprises probes for detecting gene markers, the gene markers comprising KRAS, TP53, CDKN2A, SMAD4, RNF43, TGFBR2, PIK3CA, BRAF, GNAS and CTNNB1, covering high-frequency and drug-related sites of pancreatic cancer, and the systemic tumor burden of a pancreatic cancer patient is monitored in real time and dynamically by performing targeted capture on plasma ctDNA alone or in combination with a personalized probe set.

Systems, methods, and computer program products are provided for diagnosing, prognosing, or monitoring cancer in a subject, particularly the assessment of minimal residual disease (MRD).

The invention discloses a biomarker for early diagnosis of lung adenocarcinoma and / or classification of unknown pulmonary nodules and application of the biomarker, and relates to the technical field of biological medicines. And the biomarker is piR-hsa-8429916 or piR-hsa-8393202, and the molecular marker is piR-hsa-8429916 or piR-hsa-8393202. According to the invention, the two core biomarkers piR-hsa-8393202 and piR-hsa-8429916 are successfully identified through systematic screening and verification of differentially expressed piRNA in lung adenocarcinoma tissues and serum, and the expression level of the two core biomarkers is in significant positive correlation with tumor load. The diagnostic value of the piR-hsa-8393202 and the piR-hsa-8429916 in the early diagnosis of the lung adenocarcinoma and the classification of the pulmonary nodules is obviously superior to that of the traditional CEA (Carcino Embryonic Antigen) marker. The invention provides an innovative solution for early diagnosis of lung adenocarcinoma and risk stratification of pulmonary nodule.

The invention discloses a probe set for evaluating whole-body tumor load of small cell lung cancer and application of the probe set, the probe set comprises a plurality of oligonucleotide probes for specifically capturing mutation regions of SCLC related genes in a targeted mode, and the genes are selected from TP53, RB1, CREBBP, EGFR, PTEN, PIK3CA, LRP1B and NOTCH1; and the probe set is capable of covering at least 94.9% of at least one mutation existing in an SCLC patient sample. The invention relates to the technical field of biotechnology and molecular diagnosis, and has the beneficial effects that based on a clinical queue, the probe group incorporates high-frequency mutant genes of SCLC, can be superposed with personalized probes for use, and is used for ctDNA detection of SCLC patients and evaluation of whole-body tumor load. The SCLC cancer species specific probe group provided by the invention plays a role in monitoring tumor evolution and new mutation, can overcome the space-time heterogeneity of tumors to a certain extent, and also can improve the capture efficiency at the same time.

This application belongs to the field of biomedical technology, specifically relating to the use of an ACSL4 inhibitor in the preparation of a drug for treating acute myeloid leukemia (AML). This application discloses for the first time the novel use of an ACSL4 inhibitor in the preparation of a drug for treating AML. In vitro experiments show that the ACSL4 inhibitor can effectively inhibit AML cell proliferation and promote apoptosis, without significantly affecting peripheral blood mononuclear cells in healthy controls. Animal experiments further confirm that the ACSL4 inhibitor can significantly delay disease progression in IGF2BP3-overexpressing AML mice, reduce tumor burden, and prolong the survival of NCG mice, further confirming its anti-leukemic effect in vivo.

The invention relates to the technical field of biological medicines, in particular to application of an EGFR (epidermal growth factor receptor) inhibitor in preparation of a medicine for reversing acute myeloid leukemia vinca resistance. Experimental results show that the osimertinib and the vinca are combined for use, so that the tumor load of a vinca drug-resistant model mouse can be obviously reduced, and the survival time is obviously prolonged. The combination of the two can effectively reverse the drug resistance of the vinca, and provides a new way for the drug resistance of the acute myeloid leukemia vinca.

The invention discloses application of protein nanoparticles and a composition thereof in preparation of medicines for preventing and treating tumors. The amino acid sequence of the protein nanoparticle is shown as SEQ ID NO: 12, the protein nanoparticle is combined with hPDL1-NP protein nanoparticles obtained by self-assembly of fusion proteins shown as SEQ ID NO: 20 and 21 and Ad-Re-NP protein nanoparticles obtained by self-assembly of fusion proteins shown as SEQ ID NO: 22 and 25, and the vaccine for preventing and treating tumors is prepared. The method has the obvious advantages that the tumor load is obviously reduced, the T cell infiltration is increased, and the antibody titer is maintained and increased. A novel prevention and control tool is provided for CRC high-risk groups (such as familial adenomatous polyposis patients), and a new path is opened up for immune combined treatment of metabolism-related tumors such as liver cancer and pancreatic cancer.